Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CPT1A | P50416 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rac-Etomoxir SCHEMBL15256787 | 1.00 | ABCB11 (1.00) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL954683 | 1.00 | ABCB11 (1.00) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Rac-Etomoxir SCHEMBL681359 | 1.00 | ABCB11 (1.00) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL12813827 | 0.99 | MAPT (0.98) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL5883664 | 0.99 | MAPT (0.98) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Rac-Etomoxir SCHEMBL2141141 | 0.98 | MAPT (0.95) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL22206060 | 0.93 | MAPT (0.87) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL11294309 | 0.90 | LMNA (0.82) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL14769764 | 0.90 | MAPT (0.82) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL11288224 | 0.89 | MAPT (0.80) | ABCB11LMNAMAPTMAPK1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3811 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076954-A1 | COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELLS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-03-19 | — | — | US | claimed |
| US-12544368-B2 | Compositions and methods for reducing cancer stem cells | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-02-10 | — | — | US | claimed |
| EP-4678750-A1 | REPLICON DNA, CLONING VECTOR, SCREENING KIT, SCREENING METHOD, ANTI-NOBECOVIRUS AGENT, BETA-CORONAVIRUS PROLIFERATION INHIBITOR, PAN BETA-CORONAVIRUS INHIBITOR, VIRUS PROLIFERATION INHIBITOR, HEPATITIS C VIRUS PROLIFERATION INHIBITOR, AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR VIRAL INFECTIOUS DISEASE | Kagoshima University (JP) | 2026-01-14 | — | — | EP | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| EP-3976197-B1 | THERAPEUTICS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER | LUNELLA BIOTECH INC (CA) | 2025-07-16 | — | — | EP | claimed |
| EP-3956663-B1 | A METHOD OF PROFILING THE ENERGETIC METABOLISM OF A POPULATION OF CELLS | INST NAT SANTE RECH MED (FR) | 2025-02-12 | — | — | EP | claimed |
| US-20250011719-A1 | NEW METHOD FOR IMPROVING QUALITY OF PLATELETS | SHANGHAI SYNVIDA BIOTECHNOLOGY CO. LTD. (CN) | 2025-01-09 | — | — | US | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| CN-119055773-A | Drug for reversing drug resistance of EGFR-TKI of third generation lung cancer | 华中农业大学 | 2024-12-03 | — | — | CN | claimed |
| WO-2024214687-A1 | REPLICON DNA, CLONING VECTOR, SCREENING KIT, SCREENING METHOD, ANTI-NOBECOVIRUS AGENT, BETA-CORONAVIRUS PROLIFERATION INHIBITOR, PAN BETA-CORONAVIRUS INHIBITOR, VIRUS PROLIFERATION INHIBITOR, HEPATITIS C VIRUS PROLIFERATION INHIBITOR, AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR VIRAL INFECTIOUS DISEASE | 国立大学法人 鹿児島大学 | 2024-10-17 | — | — | WO | claimed |
| EP-1226830-A2 | Combination therapy involving a sodium-hydrogen exchanger type 1 or NHE-1 inhibitor for use in treatment of ischemia | Pfizer Products Inc. (US) | 2002-07-31 | — | — | EP | claimed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | claimed |
| US-6423705-B1 | FOR ISCHEMIA BY ADMINISTERING AN NHE-1 INHIBITOR AND A SECOND COMPOUND SELECTED FROM COMPLEMENT MODULATOR, METABOLIC MODULATOR, ANTIAPOPTOTIC AGENT, NITRIC OXIDE SYNTHASE-RELATED AGENT, AND AN ENZYME/PROTEIN MODULATOR | PFIZER INC. | 2002-07-23 | — | — | US | claimed |
| WO-2002056022-A2 | DIAGNOSTICS, DRUG SCREENING AND TREATMENT FOR CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2002-07-18 | — | — | WO | claimed |
| US-6399601-B1 | ANTIDIABETIC AGENTS; NERVOUS SYSTEM DISORDERS; ANTICHOLESTEROL AGENTS | PFIZER INC. | 2002-06-04 | — | — | US | claimed |
| US-20020013268-A1 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor | FRYBURG DAVID A (US) | 2002-01-31 | — | — | US | claimed |
| EP-1145717-A2 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2001034145-A1 | TREATING CANCER BY INCREASING INTRACELLULAR MALONYL COA LEVELS | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |